Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatography–tandem mass spectrometry  by Mi, Jiaqi et al.
Institute of Materia Medica, Chinese Academy of Medical SciencesChinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2016;6(6):576–583http://dx.doi.org/10.10
2211-3835 & 2016 Ch
Elsevier B.V. This is
nCorresponding aut
E-mail addresses:
Peer review under rwww.sciencedirect.comORIGINAL ARTICLEPharmacokinetics of H002, a novel S1PR1
modulator, and its metabolites in rat blood using
liquid chromatography–tandem mass
spectrometryJiaqi Mi, Manman Zhao, Shu Yang, Shuang Yang, Jing Jin,
Xiaojian Wang, Qiong Xiao, Jinping Hun, Yan LinDepartment of Drug Metabolism, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study,
Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, State Key Laboratory of Bioactive
Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical
Sciences & Peking Union Medical College, Beijing 100050, China
Received 2 May 2016; received in revised form 10 May 2016; accepted 10 May 2016KEY WORDS
S1P receptor;
S1PR1 modulator;
Sphingosine-1-phosphate;
S1P analogue;
Metabolite;
LC–MS/MS;
Pharmacokinetics;
Periphery blood
lymphocyte16/j.apsb.2016.06.00
inese Pharmaceutica
an open access artic
hors.
hujp@imm.ac.cn (J
esponsibility of InstAbstract A rapid and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was
developed and validated for the simultaneous determination of H002 and its phosphorylated metabolite, H002-P
and hydroxylated metabolite H002-M, in rat blood. H001, an analogue of H002, was used as the internal standard.
Blood samples were prepared by simple protein precipitation. The analytes and internal standard were separated on
a Zorbax SB-C18 column with a gradient mobile phase consisting of methanol and water containing 0.1% formic
acid at a ﬂow rate of 0.2 mL/min with an operating temperature of 20 1C. The detection was performed on a triple
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H002-P. The intra- and inter-day precision (RSD%) was within 11.76%, with the accuracy (RE%) ranging from –
9.84% to 9.12%. The analytes were shown to be stable during sample storage, preparation and analytic procedures.
The method was applied to determine the pharmacokinetics of H002 in rats, and a preliminary study showed that
the pharmacokinetics of H002 correlated with its biological effect on peripheral blood lymphocytes.
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Sphingosine-1-phosphate (S1P, Fig. 1) is a bioactive sphingolipid
metabolite enriched in blood and lymph, recognized as a critical
regulator in multiple physiological pathways, such as cell growth
and suppression of apoptosis through interactions with G-protein-
coupled receptors1–3. As an identiﬁed S1P receptor (S1PR), S1PR1
was known to modulate the migration of cells between vascular
and lymphatic compartments, demonstrating its potential role as a
therapeutic target of autoimmune diseases.
FTY720, an analogue of S1P, could be reversibly phosphory-
lated to FTY720-P in vivo yielding its active form, which could
prevent lymphocyte egress from lymphoid tissues and circulation
to the periphery4. A rapid and detectable reduction of peripheral
blood lymphocytes (PBL) count, along with an increasing number
of lymphocytes in secondary lymphoid organs (SLO) is conﬁrmed
after oral administration of FTY720, presumably indicating its
major immunomodulatory mechanism5,6. However, severe adverse
effects, such as bradycardia and hypertension, may jeopardize a
patient's life since FTY720-P binds to S1PR3–5 as well as S1PR1,
raising the risk in the cardiovascular system7. In addition, FTY720
has a quite long elimination half-life in multiple species and
requires weeks and even months to allow full recovery of
immunological effects, provoking clinical concern as to patients'
susceptibility to infections8–12. Therefore, optimizing novel S1PR1
agonizts with better selectivity and pharmacokinetic properties
seems crucial to achieve satisfactory therapy.
Amino-propylene-glycol derivatives have been recently shown
to be promising immune-modulators with lower potency for the
S1PR3 receptor, attenuating the risk of adverse effects
13,14. Among
them, H002 (2-amino-2-(2-(4ʹ-(2-ethyloxazol-4-yl)-[1,1ʹ-biphenyl]-4-
yl)ethyl)propane-1,3-diol, previously named SYL927, Fig. 1), a
synthetic chemical entity, was found to be reversibly phosphorylated
to H002-P (Fig. 1) in vivo, and showed receptor selectivity for S1PR1
and less effect on the cardiovascular system as compared to
FTY72015. The hydroxylated metabolite H002-M (Fig. 1) showed
little effect on S1PR. Furthermore, pharmacodynamic studies of
H002 revealed a promising therapeutic effect in an experimental
autoimmune psoriasis model.
Despite extensive research on the pharmacodynamics of H002,
little is known about its pharmacokinetics. The introduction of a
phosphate group increased the polarity of H002-P signiﬁcantly,
resulting in decreased solubility in organic solvents compared toFigure 1 Chemical structures of S1P, H002, H002-P, H002-M and
H001 (IS).the parent drug and its hydroxylated metabolite. Therefore, it is
challenging to develop a reliable method to obtain the satisfactory
recovery and sensitivity for each analyte. The objective of this
study was to develop a simple, sensitive, and accurate LC–MS/MS
method for the simultaneous determination of H002, H002-P and
H002-M in rats after oral administration of H002, along with
measurement of PBL counts to illustrate the relationship between a
decrease in PBL counts and drug concentration in blood.2. Experimental
2.1. Chemicals and reagent
H002 (purity 99.1%), H002-P (purity 96.4%), H002-M (purity 90.0%)
and the internal standard (IS) H001 (2-amino-2-(2-(4ʹ-(2-propyloxazol-
4-yl)-[1,1ʹ-biphenyl]-4-yl)ethyl)propane-1,3-diol, Fig. 1, purity 99.9%)
were kindly provided by Laboratory of Chemical Synthesis (Institute
of Materia Medica, Chinese Academy of Medical Science). Methanol
was of HPLC grade (Fisher, USA). All other chemicals were of
analytical reagent grade. HPLC grade water was obtained using a
Milli Q system (Millipore, MA, USA).
2.2. Instruments
The separation was carried out on an Agilent 1260 series HPLC
system (Agilent, USA) with an injection of 10 μL sample onto a
Zorbax SB-C18 column (100 mm 2.1 mm, 3.5 μm, Agilent,
USA). The temperature of the autosampler was set at 10 1C
throughout the analysis. Mobile phase A was 0.1% (v/v) formic
acid, mobile phase B was methanol with 0.1% (v/v) formic acid, and
the ﬂow rate was 0.2 mL/min with an operating temperature of
20 1C. The initial condition for the HPLC gradient was 70:30 (A:B).
From 2.5 to 2.6 min, the mobile phase composition changed linearly
to 5:95 (A:B). This condition was held until 4.6 min, followed by
re-equilibration at 70:30 (A:B) until 9.0 min.
Mass spectrometric analysis was performed on the API 4000
triple quadruple mass spectrometer (AB SCIEX, USA) in positive
electrospray ionization (ESI) mode. The optimized ion spray
voltage and temperature were set at 5500 V and 500 1C. The
collision gas (CAD) and curtain gas (CUR) were nitrogen
delivered at 6 and 25 psi, while both ion source gas 1 (GS1)
and ion source gas 2 (GS2) were set at 50 psi. The collision energy
(CE) of H002, H002-P, H002-M and IS were 35, 25, 25 and
26 eV, respectively. The MS recordings were carried out in
multiple reaction monitoring (MRM) mode with speciﬁc ion
transitions of protonated precursor ion to product ion at
m/z 367.2-350.1 for H002, m/z 447.1-320.1 for H002-P,
m/z 383.3-366.4 for H002-M and m/z 381.2-364.2 for IS.
In addition, the MEK-7222K type blood cell analyzer (NIHON
KOHDEN, Japan) was used to count PBL.
2.3. Preparation of standard and quality control samples
To prepare the stock solutions, H002, H002-M and H001 (IS)
were dissolved in methanol at 1 mg/mL, while H002-P was
0.5 mg/mL, taking solubility into consideration. Working stan-
dards were prepared by dilution of stock solution in methanol to
obtain the desired concentrations of 1, 2.5, 5, 10, 25, 100, 250,
375, 500 ng/mL for H002 and H002-M, 2.5, 5, 10, 25, 50, 100,
250, 375, 500 ng/mL for H002-P. The IS spiking solution was
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nol. All working solutions were stored at –20 1C until use.
Calibration standard samples were prepared by adding 20 μL of
each corresponding working solution and IS working solution
along with 120 μL acetonitrile into 100 μL of blank rat blood,
giving the blood concentrations of 0.2, 0.5, 1, 2, 5, 20, 50, 75,
100 ng/mL for H002 and H002-M, 0.5, 1, 2, 5, 10, 20, 50, 75,
100 ng/mL for H002-P and 60 ng/mL for IS. The quality control
(QC) samples (0.5, 25, 80 ng/mL for H002 and H002-M, 1.5, 25,
80 ng/mL for H002-P) were prepared in a manner similar to that
used for preparation of the calibrator samples.
2.4. Preparation of samples
A 20 μL of IS working solution (300 ng/mL) and 180 μL
precipitant (a mixture of 120 μL acetonitrile and 60 μL methanol)
were added into 100 μL of rat blood. The mixture was vortex-
mixed, followed by centrifugation at 14,000 rpm (Thermo Scien-
tiﬁc Heraeus Fresco 21 centrifuge, ThermoFisher Scientiﬁc,
Germany) for 5 min. A 10 μL supernatant sample was injected
into LC–MS/MS system for analysis.
2.5. Method validation
2.5.1. Selectivity
Selectivity was evaluated by analyzing six independent blank rat blood
samples to investigate the potential interferences at peak regions for
H002, H002-P, H002-M and IS. Their chromatographic peaks were
identiﬁed on the basis of their retention times and MRM responses.
2.5.2. Linearity, precision and accuracy
To determine the linearity of the calibration curve, a peak–area
ratio (analyte/IS) versus the nominal concentration of analytes with
weighted (1/X2) least square linear regression was calculated. The
calibration curve required a correlation coefﬁcient (r2) of 0.99 or
better.
The precision and accuracy of the assay were detected by
analysis of QC samples. Intra-day precision and accuracy was
estimated by analyzing ﬁve QC samples at low, medium and high
concentration levels within one day, while the inter-day precision
and accuracy were performed on ﬁve consecutive days. The
variability of determination was expressed as the relative standard
deviation (RSD, %) and the accuracy was expressed as the relative
error (RE, %). The criteria for acceptability included accuracy
within 715% RE from the nominal values and a precision within
715% RSD, except for the lower limit of quantitation (LLOQ),
which should not exceed 720% of accuracy as well as precision.
2.5.3. Matrix effects
The matrix effect was deﬁned as the ion suppression/enhancement
on the ionization of analytes, which was evaluated by comparing
the responses with deproteinized samples of six spiked rat blood
QC samples to those of standard solutions at equivalent concen-
trations. Three QC concentrations were analyzed in ﬁve replicates.
2.5.4. Recovery
The recoveries of H002, H002-P and H002-M from blood were
calculated by comparing the peak area of the extracted QC
samples to that of analytes spiked to the blank sample extracts
at the same concentration. The recoveries of two compounds in rat
blood were examined at least ﬁve times.2.5.5. Stability studies
Three freeze–thaws, long-term, short-term and post-preparative
stabilities of H002, H002-P and H002-M in rat blood were tested
using low-, mid- and high-quality control samples. Freeze–thaw
stability was evaluated in up to three cycles, in which the samples
were frozen and stored at –20 1C for 24 h, then thawed on ice. For
short-term stability, fresh blood samples were kept on ice for 6 h
before preparation. The stability of prepared blood samples was
determined after keeping them at room temperature for 24 h or in
the autosampler rack at 10 1C for 48 h. Long-term storage stability
was acquired by assaying QC blood samples after storage at
–20 1C for 30 days and 3 months. Dilution stability was evaluated
using a spiked sample at a concentration higher than the upper
limit of quantiﬁcation samples (ULOQ). The result was obtained
by comparing the back-calculated value of the sample after being
diluted 10 times with the nominal value.
2.5.6. Carry-over
Carry-over was evaluated by triplicated measurements of a blank
sample following the injection of the highest calibration standard.
It was considered negligible if the measured peak area was no
more than 20% of the area of LLOQ16,17.
2.6. Pharmacokinetic study
To assess the applicability of present method, the pharmacokinetics of
H002, H002-P and H002-M were investigated in male Sprague–
Dawley (SD) rats after oral administration of H002 at 3, 10 and
30 mg/kg. The rats (180–220 g) were purchased from Beijing Vital
River Experimental Animal Co., Ltd. All animal protocols were
approved by Institute Animal Care and Welfare Committee. The rats
were allowed free access to water and chow diet and fasted overnight
with water before pharmacokinetic experiments.
The dosing solutions were prepared by suspending H002 in 0.5%
hydroxypropyl methyl cellulose (HPMC). The rats were given H002
at dose of 3, 10 and 30 mg/kg via gavage. Blood samples were taken
from each animal by orbital bleeding via capillary tubes at 5, 15,
30 min, 1, 2, 4, 6, 8, 12, 24, 36, 48 and 72 h after dosing. The blood
samples were placed on ice and immediately treated as described in
Section 2.4 and frozen at –20 1C until analyzed.
The pharmacokinetic parameters of H002, H002-P and H002-M
were calculated using WinNonlin software version 6.3 based on
non-compartmental analysis (Pharsight Corporation, Mountain
View, USA). The blood concentrations of the tested compounds
were expressed as mean7SD.
2.7. Measurement of peripheral blood lymphocytes
Ten male SD rats were randomly divided into two groups. H002
(3 mg/kg) was given to rats by gavage, while the rats in control group
received the same volume of vehicle. A 20 μL sample of blood was
collected from the tail vein at 0, 2, 4, 8, 12, 24, 36, 48 and 72 h after
dosing and the PBL counts were measured immediately (n¼5)18.3. Results and discussion
3.1. Method development
Better speciﬁcity and sensitivity for the determination of H002,
H002-P, H002-M and IS were obtained in positive mode compared
Figure 2 MS/MS spectra of (A) H002, (B) H002-P, (C) H002-M and (D) IS.
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full-scan Q1 mode showed a protonated molecular ion [MþH]þ as
the base peak, m/z 367.2 for H002, m/z 447.1 for H002-P, m/z 383.3
for H002-M and m/z 381.2 for IS. As shown in Fig. 2, the most
abundant and stable product ions were at m/z 350.1, 320.1, 366.4
and 364.2 for H002, H002-P, H002-M and IS, respectively,
after fragmentation in the collision cell. The mass spectrometric
parameters, such as collision energy, spray voltage, and
source temperature, were optimized for highest and most stable
signal.
To achieve more satisfactory chromatographic behavior, differ-
ent HPLC parameters including type of column material, mobile
phase and appropriate ﬂow rate were tested and compared. Zorbax
SB-C18 column (3.5 μm, 100 mm 2.1 mm) was adopted to
obtain sharp peak shapes for each analyte. In this experiment,
methanol/water containing 0.1% formic acid (v/v) at a ﬂow rate of
0.2 mL/min was found to be suitable for the determination of
electrospray responses of analytes.
3.2. Method validation
3.2.1. Selectivity
As shown in Fig. 3, there was no signiﬁcant interference from rat
blood observed at the retention times of the analytes and IS. The
other peak in H002-M (Fig. 3 C) is speculated to be a relevant
impurity peak, which could be an isomer produced in ratblood and needs further study. The retention times of H002,
H002-P, H002-M and IS were 6.94, 7.16, 6.56 and 7.09 min,
respectively.3.2.2. Linearity and range
The liner relationships were found between peak area ratios and
analyte concentrations within the range of 0.2–100 ng/mL for H002
and H002-M, and 0.5–100 ng/mL for H002-P. The regression
equations obtained by least squared regression were y¼0.0157 x
þ0.00123 (r2¼0.9980, n¼5) for H002, y¼0.0239 xþ0.00326
(r2¼0.9956, n¼5) for H002-P and y¼0.00623 xþ 0.00101
(r2¼0.9953, n¼5) using weighing factor 1/X2. The observed
deviations were within 715% for all calibration concentrations.
The LLOQ was set at 0.2 ng/mL for H002 and H002-M, 0.5 ng/mL
for H002-P, which was appropriate for pharmacokinetic studies.3.2.3. Precision and accuracy
The precision and accuracy of the method for H002, H002-P and
H002-M were assessed by determining QC samples (n¼5) at three
concentrations and are summarized in Table 1. The intra- and
inter-day precision of H002, H002-P and H002-M were within
11.76%, and the accuracy was found to be less than79.84%. The
results indicate that the present method is reliable and reproducible
for the quantitative determination of analytes.
Table 1 Intra-day and inter-day accuracy and precision of
measurement of H002, H002-P and H002-M in rat blood
(n¼5).
Sample Nominal
Conc.
(ng/mL)
Observed
Conc.
(ng/mL)
Accuracy
(RE, %)
Precision
(RSD, %)
H002
Intra-day 0.5 0.5070.03 0 6.00
25 27.1070.68 8.40 2.51
80 81.3471.50 1.78 1.84
Inter-day 0.5 0.5170.05 2.00 9.80
25 27.2870.78 9.12 2.86
80 79.5673.30 –0.55 4.15
H002-P
Intra-day 1.5 1.4370.09 –4.67 6.29
25 24.1470.73 –3.36 3.02
80 84.0073.67 5.00 4.37
Inter-day 1.5 1.4470.13 –4.00 9.03
25 25.2870.63 1.12 2.49
80 81.0473.91 1.30 4.82
Figure 3 Typical MRM chromatograms of H002, H002-P, H002-M
and IS. (A) Blank rat blood; (B) LLOQ sample and (C) rat blood
sample at 15 min post dose of H002 (3 mg/kg) spiked with IS.
(a) H002, (b) H002-P, (c) H002-M, (d) IS.
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The mean matrix effect values were 104.1%, 101.5% and 98.1%
for H002, 97.6%, 102.1% and 99.9% for H002-P, and 95.0%,
101.9% and 99.9% for H002-M at low, medium and high
concentration levels, respectively, suggesting that the matrix
effect on the ionization was not signiﬁcant under current
conditions.H002-M
Intra-day 0.5 0.5070.04 0 8.00
25 22.5470.55 –9.84 2.44
80 72.7671.04 –9.05 1.43
Inter-day 0.5 0.5170.06 2.00 11.76
25 23.0871.30 –7.68 5.63
80 73.6474.43 –7.95 6.023.2.5. Recovery and stability
The recoveries from rat blood were 87.4%–106.0%, 94.8%–
109.6% and 94.9%–113.3% for H002, H002-P and H002-M at
three concentration levels.
All stability results are summarized in Table 2. The blood
samples were shown to be stable after being placed on ice for 6 h,
at room temperature for 24 h, stored at 20 1C for 30 days or3 months, and through three freeze–thaw cycles or
dilution. Furthermore, samples after treatment were stable at
10 1C in the autosampler for a period of 48 h, indicating that a
large number of samples could be determined in each
analytical run.
3.2.6. Carry-over
The analyte peak areas after triplicate injections of a blank blood
sample and the highest calibration standard samples were less
than 10% of LLOQ, demonstrating a negligible carry-over
effect.
3.3. Pharmacokinetic study and PBL counts
The present method was applied to determine the blood concen-
tration of H002, H002-P and H002-M in rats after oral adminis-
tration of H002. According to previous pharmacological studies
(unpublished data), oral administration of H002 at 3 mg/kg was
found to be the effective dose in rats. Thus, we chose three doses
(3, 10 and 30 mg/kg) to investigate whether H002 underwent
linear pharmacokinetics in the range of 3–30 mg/kg. The mean
concentration–time curve (n¼5) is illustrated in Fig. 4 and the
pharmacokinetic parameters are listed in Table 3. The Cmax and
Tmax were obtained directly from the pharmacokinetic data while
other parameters were calculated with WinNonlin software. The
results show that the Tmax of both H002-P and H002-M were 2–4 h
Table 2 Stability of H002, H002-P and H002-M in rat blood (n¼5).
Condition H002 H002-P H002-M
Nominal
Conc.
(ng/mL)
Observed
Conc.
(ng/mL)
RE (%) Nominal
Conc.
(ng/mL)
Observed
Conc.
(ng/mL)
RE (%) Nominal
Conc.
(ng/mL)
Observed
Conc.
(ng/mL)
RE (%)
Store at 4 1C (6 h) 0.5 0.4970.01 –2.00 1.5 1.6270.07 8.00 0.5 0.4970.02 –2.00
25 25.7470.23 2.96 25 23.1070.43 –7.60 25 26.7871.51 7.12
80 77.7271.86 –2.85 80 72.2672.06 –9.68 80 79.6672.34 –0.43
Room
Temperature
(24 h)
0.5 0.5070.03 0.00 1.5 1.4170.10 –6.00 0.5 0.4970.04 –2.00
25 26.2470.61 4.96 25 23.5870.59 –5.68 25 22.4270.63 –10.32
80 85.7670.85 7.20 80 83.5671.34 4.45 80 75.3071.20 –5.88
Autosampler
Rack at 10 1C
(48 h)
0.5 0.5470.03 8.00 1.5 1.5370.05 2.00 0.5 0.4770.04 –6.00
25 26.4870.90 5.92 25 25.7871.09 3.12 25 22.3071.12 –10.80
80 84.0871.00 5.10 80 81.5274.02 0.67 80 71.1471.44 –11.08
Store at –20 1C
(7 d)
0.5 0.4770.02 –6.00 1.5 1.5170.15 2.40 0.5 0.4570.01 –10.00
25 25.1870.46 0.72 25 25.6070.45 –2.68 25 23.4070.62 –6.40
80 76.8070.51 –4.00 80 77.8672.53 2.39 80 82.8873.55 3.60
Store at –20 1C
(30 d)
0.5 0.5170.04 2.00 1.5 1.4570.09 –3.33 0.5 0.4870.05 –4.00
25 25.8270.97 3.28 25 26.9070.99 7.60 25 22.9470.38 –8.24
80 77.4872.75 –3.15 80 77.6272.88 –2.98 80 77.3272.84 –3.35
Store at –20 1C
(3 months)
0.5 0.4770.02 –6.00 1.5 1.3170.11 –12.67 0.5 0.4670.03 –8.00
25 24.7070.75 –1.20 25 25.1270.91 0.48 25 25.7670.86 3.04
80 75.3670.55 –5.80 80 77.1873.37 –3.53 80 82.2273.40 2.78
Three freeze–
thaw cycles
0.5 0.5170.01 2.00 1.5 1.4170.09 –6.00 0.5 0.4870.01 –4.00
25 27.1870.33 8.72 25 24.7070.41 –1.20 25 22.8670.85 –8.56
80 85.9870.98 7.48 80 80.4071.23 0.50 80 77.0071.25 –3.75
Dilution stability
(factor: 10)
80 73.0970.94 –8.64 80 72.4570.65 –9.44 80 83.4970.94 4.36
Figure 4 Mean blood concentration curves of (A) H002, (B) H002-P and (C) H002-M in rats after oral administration of H002 at 3, 10 and
30 mg/kg.
Pharmacokinetics of H002 in rat 581later than that of H002, while the Cmax of H002-P and H002-M
were 2.06–2.62- and 0.43–0.61-fold of the parent drug, respec-
tively. The AUC0–t and Cmax values obtained from three oral dose
levels showed a lack of linearity, along with the extension of t1/2z
and MRT0–t and reduction of Vz and CLz with increased dosage,
suggesting the saturation of absorption and elimination. The
results indicate nonlinear pharmacokinetics for H002, H002-P
and H002-M in rats from 3 to 30 mg/kg.
PBL counting is a speciﬁc and remarkable indicator for
lymphocyte homing. As shown in Fig. 5, PBL counts decreaseddramatically and were maintained for 8 h in rats after oral
administration of H002 at 3 mg/kg, while high blood concentra-
tions of the three analytes were observed over the same period.
Compared with FTY7208, a quicker recovery of lymphopenia after
discontinuation was observed due to the rapid elimination of H002
in vivo, which is a desirable pharmacokinetic characteristic for
S1PR1-selective agonizts. For a better understanding and predic-
tion of H002 concentration–effect relationship in vivo, a
mechanism-based PK/PD model will be developed in future
studies.
Table 3 Pharmacokinetic parameters of H002, H002-P and H002-M in male rats after a single oral dose of H002 at 3, 10 and 30 mg/kg
(n¼5).
Parameter Unit H002 (mg)
3 10 30
t1/2z h 13.4273.16 10.4171.84 18.3771.19
Tmax h 1.2071.57 4.0071.41 2.0071.22
Cmax ng/mL 22.2078.16 55.30717 267.60756.99
AUC0–t (ng  h)/mL 125.79724.38 630.277181.38 3782.587663.05
Vz L/kg 457.53767.33 245.31750.79 215.78743.99
CLz L/h/kg 24.4275.16 16.7474.28 8.1071.34
MRT0–t h 11.1772.57 11.7572.4 14.6373.09
Parameter Unit H002-P (mg)
3 10 30
t1/2z h 12.4370.94 12.6571.36 16.0071.63
Tmax h 6.8071.10 6.0072.00 5.6073.58
Cmax ng/mL 45.76714.78 161.22751.54 567.207111.45
AUC0–t (ng  h)/mL 464.82793.83 2348.967733.10 10802.8972551.27
Vz L/kg 118.67728.19 81.75720.13 65.5479.46
CLz L/h/kg 6.6171.39 4.5371.16 2.8870.62
MRT0–t h 13.0872.13 14.0472.90 16.7673.40
Parameter Unit H002-M (mg)
3 10 30
t1/2z h 5.9571.12 7.0770.62 16.6271.39
Tmax h 4.8071.10 6.8073.35 6.0073.46
Cmax ng/mL 13.0672.84 33.50710.56 114.46718.14
AUC0–t (ng  h)/mL 127.4079.10 427.18733.89 2213.587286.86
Vz L/kg 330.56760.12 239.14721.36 202.54739.94
CLz L/h/kg 23.6171.74 23.5071.81 13.7171.68
MRT0–t h 10.0371.69 11.3271.82 16.1972.18
Figure 5 PBL counts–time curve in rats after oral administration of
H002 (3 mg/kg) and vehicle.
Jiaqi Mi et al.5824. Conclusions
In conclusion, the newly developed and validated LC–MS/MS
method with protein precipitation provided an accurate, sensitive
and simple assay for the simultaneous determination of H002,
H002-P and H002-M, and was applied for the pharmacokinetic
analysis of H002 in rats after oral administration. A preliminary
relationship between the drug blood concentration and peripheral
lympho-depletion was also observed.Acknowledgments
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